INCY - Incyte Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
62.91
-0.08 (-0.13%)
As of 12:45PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close62.99
Open63.47
Bid62.96 x 200
Ask63.04 x 200
Day's Range61.61 - 63.47
52 Week Range61.30 - 140.11
Volume1,550,882
Avg. Volume2,434,927
Market Cap13.324B
Beta1.12
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Lessons to Learn From April's Biotech Blowups
    Motley Foolyesterday

    Lessons to Learn From April's Biotech Blowups

    Three biotechs reported devastating clinical trial failures this month. Here are the important takeaways.

  • TheStreet.com2 days ago

    Eli Lilly CEO Expresses Confidence in New Rheumatoid Arthritis Drug

    rheumatoid arthritis drug baricitinib, Eli Lilly chairman and CEO David Ricks on an earnings call Tuesday expressed confidence in the benefit-risk profile of both doses of the treatment. The advisory panel recommended that the FDA approve the 2-mg dose of baricitinib, but not the 4-mg dose for the proposed indication based on the adequacy of the safety and benefit-risk profiles. "While we are pleased that the FDA's arthritis advisory committee supported the efficacy of both 2 mg and 4 mg of baricitinib in RA and 2 mg overall, we are disappointed that the committee did not recommend approval of the 4-mg dose," Ricks said.

  • MarketWatch2 days ago

    Eli Lilly, Incyte shares drop after mixed FDA drug recommendation

    Eli Lilly & Co. shares dropped nearly 3% in premarket trade Tuesday after the company's rheumatoid arthritis therapy baricitinib was recommended for Food and Drug Administration approval at the 2-mg dose, but not the 4-mg dose. Incyte Corp. , a partner on the drug, had its shares drop nearly 5% premarket. The recommendation, made by the FDA's arthritis advisory committee late Monday, was based on concerns about the 4-mg dose's safety and risks relative to its benefits.

  • Eli Lilly's earnings beat expectations, and its improved outlook overcomes regulatory setback
    CNBC2 days ago

    Eli Lilly's earnings beat expectations, and its improved outlook overcomes regulatory setback

    Eli Lilly shares gain after the drugmaker beats first-quarter earnings expectations.

  • Reuters3 days ago

    FDA panel against higher dose of Lilly-Incyte arthritis drug

    An arthritis drug developed by Eli Lilly & Co and Incyte Corp should not be approved at a 4-milligram dose, advisers to the U.S. FDA voted on Monday, in a setback to the drugmakers that were counting on the treatment as a future blockbuster.

  • 3 Biotech Stocks With Major Catalysts Incoming
    Motley Fool6 days ago

    3 Biotech Stocks With Major Catalysts Incoming

    Highly anticipated events expected in the weeks ahead could set these three biotechs up for long-term success.

  • Eli Lilly's Blockbuster Resurrection Story Has Holes
    Bloomberg7 days ago

    Eli Lilly's Blockbuster Resurrection Story Has Holes

    Its arthritis drug's new lease on FDA life apparently comes with conditions.

  • MarketWatch7 days ago

    Gilead shares drop on FDA concerns with similar Eli Lilly, Incyte drug

    Gilead Sciences Inc. shares dropped 2.1% in moderate Thursday trade after a Food and Drug Administration briefing document raised safety questions about a similar Eli Lilly & Co. and Incyte Corp. drug. ...

  • MarketWatch7 days ago

    Eli Lilly, Incyte shares fall after FDA cites issues with rheumatoid arthritis drug

    Eli Lilly & Co. shares fell 1.8% premarket and Incyte Corp. shares dropped 4.5% premarket on Thursday after a Food and Drug Administration briefing document raised issues with their rheumatoid arthritis drug baricitinib. The drug will go up before a FDA arthritis advisory committee meeting on Monday. The FDA often follows an advisory committee's recommendation, though there are exceptions.

  • Reuters7 days ago

    FDA staff cites safety issues for Lilly, Incyte's rheumatoid arthritis drug

    The U.S. Food and Drug Administration staff on Thursday flagged concerns about potentially fatal blood clots from higher doses of Eli Lilly and Co and Incyte Corp's rheumatoid arthritis drug. An independent ...

  • Motley Fool10 days ago

    What Incyte's Phase 3 Fail Means for Immuno-Oncology

    Incyte’s phase 3 Epacadostat trial wasn’t so hot, and stocks all across biotech are feeling the burn.

  • NewLink Shares Bite The Dust After Merck-Incyte Melanoma Failure
    Investor's Business Daily10 days ago

    NewLink Shares Bite The Dust After Merck-Incyte Melanoma Failure

    NewLink toppled Monday after it scrapped a late-stage study of its immuno-oncology drug in combination with drugs from Merck and Bristol.

  • Motley Fool10 days ago

    What's Next for Incyte?

    With a key pipeline drug nixed, Incyte has a few more question marks on the horizon than it did before.

  • MarketWatch10 days ago

    NewLink shares fall on late-stage trial changes

    NewLink Genetics Corp. shares fell as much as 15% in premarket trade Monday after the company said it won't proceed as planned with a late-stage trial of its indoximod for advanced melanoma. The company ...

  • The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte
    Zacks10 days ago

    The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte

    The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte

  • Motley Fool13 days ago

    What Happened With Incyte's IDO Inhibitor Flop

    Investor confidence in epacadostat was through the roof, and the drug's phase 3 flop crushed the stock in a big way.

  • Pharma M&A Active This Week: 4 Potential Buyout Targets
    Zacks13 days ago

    Pharma M&A Active This Week: 4 Potential Buyout Targets

    Novartis and Alexion announce respective acquisitions of AveXis and Wilson Therapeutics for a pipeline boost. We suggest four stocks as hot acquisition picks this year.

  • Incyte: S&P 500’s Top Gainer on April 12
    Market Realist13 days ago

    Incyte: S&P 500’s Top Gainer on April 12

    The S&P 500’s top gainers on April 12 were: Incyte (INCY) gained 5.3%. Micron Technology (MU) gained 4.2%. Host Marriott Financial Trust (HST) gained 4.1%. Deere & Company (DE) gained 4.1%. Discovery (DISCK) gained 3.9%. Incyte 

  • Motley Fool14 days ago

    Why One Drug Flop Tanked Incyte's Stock

    Biotech is risky business, and Incyte shareholders have not had a good week after a key drug flopped its phase 3.

  • Barrons.com14 days ago

    The Biggest Movers: Incyte Excites; L Brands Slides

    Incyte (INCY) popped to the top of among S&P 500 stock performers, helped by an analyst upgrade. Incyte added $3.54, or 5.3%, to $69.83.  The S&P 500 gained 21.80 points, or 0.83%, to 2663.99. UBS's Carter ...

  • Why GoPro, Incyte, and Wynn Resorts Jumped Today
    Motley Fool14 days ago

    Why GoPro, Incyte, and Wynn Resorts Jumped Today

    Find out which of these companies jumped on takeover chatter.

  • Investopedia14 days ago

    3 Biotech Stocks Analysts Have Been Too Bullish On

    Regeneron, Incyte and Tesaro have all had a terrible start to 2018, with shares down 14% or more.

  • Incyte Advances R&D Strategy with Multiple Partnerships
    Market Realist14 days ago

    Incyte Advances R&D Strategy with Multiple Partnerships

    In January 2015, Incyte (INCY) entered an antibody discovery collaboration with Agenus (AGEN), which was later amended in February 2017. As per the amended agreement, the ongoing research programs for the development of checkpoint modulator antibodies targeted at GITR and OX40 have been converted from co-funded ones to being fully funded by Incyte. Additionally, the profit-sharing arrangement for these research programs has been converted into royalty-bearing programs.

  • Why Did Bristol-Myers Squibb Stock Fall More Than 3% on April 6?
    Market Realist14 days ago

    Why Did Bristol-Myers Squibb Stock Fall More Than 3% on April 6?

    On April 6, 2018, Incyte (INCY) stock fell nearly 20%, triggered by news of the failure of the clinical trial for its skin cancer drug. The trial is for the assessment of the combo-therapy approach of Incyte’s epacadostat and Merck’s (MRK) Keytruda for the treatment of skin cancer. The Phase 3 trial results were unexpectedly found to yield unsuccessful results since it did not achieve the main goal of the study.

  • Olumiant Could Boost Incyte’s Revenues
    Market Realist14 days ago

    Olumiant Could Boost Incyte’s Revenues

    In February 2017, Eli Lilly (LLY) secured approval for Olumiant (baricitinib) from the European Medicines Agency (or EMA) for patients suffering from moderate-to-severe rheumatoid arthritis (or RA) and who did not respond sufficiently or could not tolerate disease-modifying antirheumatic drugs (or DMARDs). In July 2017, the drug was approved by the Japan Ministry of Health, Labor, and Welfare for RA patients who don’t respond sufficiently to standard-of-care treatment options. The drug is also approved in Switzerland for the RA indication.